Get the Stockscreener App
6.24
2.19%
-0.14
Vanda Pharmaceuticals Inc stock is traded at $6.24, with a volume of 596.28K.
It is down -2.19% in the last 24 hours and up +3.48% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
See More
Previous Close:
$6.38
Open:
$6.35
24h Volume:
596.28K
Relative Volume:
0.58
Market Cap:
$375.25M
Revenue:
$217.78M
Net Income/Loss:
$-239.55M
P/E Ratio:
-1.541
EPS:
-4.0492
Net Cash Flow:
$-127.30M
1W Performance:
+0.48%
1M Performance:
+3.48%
6M Performance:
-14.87%
1Y Performance:
+25.05%
1-Day Range:
$6.145
$6.355
1-Week Range:
$6.145
$6.615
52-Week Range:
$4.14
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.24 | 375.25M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Initiated | Truist | Buy |
| Nov-05-25 | Initiated | B. Riley Securities | Buy |
| Oct-31-24 | Initiated | H.C. Wainwright | Buy |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits
Vanda Pharmaceuticals plans fireside chat at Boston investor summit - Stock Titan
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - PR Newswire
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on FDA designation - Investing.com India
Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S - AllSci
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy - Stocktwits
Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S - Quantisnow
Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market - ad-hoc-news.de
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug - Stocktwits
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
VNDAVanda Pharmaceuticals Inc Volatility & Greeks - Finviz
McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY® - McDermott Will & Schulte
Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA) - Yahoo Finance
Vanda Pharmaceuticals | 3: Initial statement of beneficial ownership of securities- McGuire Daniel Patrick - Moomoo
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group 2026 Past Winners - WTA Tennis
Vanda Pharmaceuticals Mallorca Women's Championships presented by Ecotrans Group - WTA Tennis
Watch Vit Kopriva vs Ignacio Buse - tod.tv
Price to book forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – FWB:VM4 - TradingView
Price to earnings forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3 - TradingView
Enterprise value to EBIT forward of Vanda Pharmaceuticals Inc. – FWB:VM4 - TradingView
Price to earnings forward of Vanda Pharmaceuticals Inc. – FWB:VM4 - TradingView
Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA - TradingView
Net current asset value per share of Vanda Pharmaceuticals Inc. – LSX:A0JJT3 - TradingView
Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3 - TradingView
Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda - Barchart.com
Athletics announces jersey patch partnership with biopharmaceutical company - The GW Hatchet
Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA) - TradingView
VNDA Forecast — Price Target — Prediction for 2027 - TradingView
Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner - George Washington University Athletics
Watch VANDA Pharmaceuticals Berlin Tennis Open (Quarterfinals) | Disney+ - Disney Plus
Licensable picture: VANDA Pharmaceuticals Berlin Tennis Open 2026 - reutersconnect.com
VNDA|Vanda Pharmaceuticals Inc|Price:6.000|Chg%:0.20 - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):